FDA-cleared profile

JLK-ICH

JLK, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT

Clinical role
Triage or notification support
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Notifications are not diagnostic. Users must review non-compressed images on a diagnostic viewer and perform full clinical assessment; cases are not removed or deprioritized in the standard worklist.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM non-contrast head CT from DICOM-compliant devices
  • Who uses it?Intended users: Hospital networks, trained clinicians and notified medical specialists
  • What does the software produce?Output: Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.
  • What is its most important limitation?Key limitation: Notifications are not diagnostic. Users must review non-compressed images on a diagnostic viewer and perform full clinical assessment; cases are not removed or deprioritized in the standard worklist.

Clinical takeaway. Clinical role: Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT

Evidence takeaway. Evidence from the reviewed source record: Standalone retrospective study of 376 US NCCTs (188 ICH-positive, 188 negative) with two ABR-certified neuroradiologists and third-reader consensus. Test data were newly acquired and independent of development data.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Triage or notification support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM non-contrast head CT from DICOM-compliant devices
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Hospital networks and trained clinicians identifying and communicating images of specific patients to specialists; the device analyzes non-contrast CT images of the head to detect intracranial hemorrhage.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "JLK-ICH is a notification-only, parallel workflow tool that is intended to assist hospital networks and trained clinicians to identify and communicate images of specific patients to specialists, independent of the standard of care workflow." … "Specifically, the device analyzes non-contrast CT images of the head to detect intracranial hemorrhage (ICH).". Read from the exact FDA decision document on 2026-11-14.

Intended users
Hospital networks, trained clinicians and notified medical specialists
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Notifications are not diagnostic. Users must review non-compressed images on a diagnostic viewer and perform full clinical assessment; cases are not removed or deprioritized in the standard worklist.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Standalone retrospective study of 376 US NCCTs (188 ICH-positive, 188 negative) with two ABR-certified neuroradiologists and third-reader consensus. Test data were newly acquired and independent of development data.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone retrospective study of 376 US NCCTs (188 ICH-positive, 188 negative) with two ABR-certified neuroradiologists and third-reader consensus. Test data were newly acquired and independent of development data.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
97.3% (95% CI 94.8%-99.5%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Case-level ICH detection in the 376-scan standalone study; not a subtype-specific claim.

Reported specificity
97.9% (95% CI 95.5%-99.5%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Sensitivity

97.3 %

  • EndpointCase-level ICH detection
  • Population376 US NCCTs, 188 positive and 188 negative
  • Tested versionJLK-ICH in K243363

Specificity

97.9 %

  • EndpointCase-level ICH detection
  • Population376 US NCCTs, 188 positive and 188 negative
  • Tested versionJLK-ICH in K243363

K243363 standalone ICH notification performance study

  • DesignRetrospective standalone performance with independent test data and neuroradiologist consensus reference
  • Population376 US NCCT scans; 188 ICH positive and 188 negative
  • Scopeexact submission
  • Tested versionJLK-ICH in K243363
  • Samplen=376
  • IndependenceIndependence not established

K243363

Deep learning-assisted detection of intracranial hemorrhage: validation and impact on reader performance

  • DesignRetrospective reader-performance validation
  • Population1,370 NCCT examinations at one tertiary Korean hospital
  • Scopeproduct family
  • Tested versionJLK-ICH; exact K243363 version not established
  • Samplen=1370
  • Sites1
  • IndependenceSponsor or vendor study

PMID:40116947 · doi:10.1007/s00234-025-03560-x

Publication identifies company-employed authors. It is family contextual evidence, not an independent replication or a substitute for FDA study results.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-contrast head CT from DICOM-compliant devices

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary

  2. Routing

    Source context, not route validation: DICOM-compatible image transfer and processing; notifications are delivered through the JLK mobile application.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary

  3. AI processing

    Source context, not route validation: The exact FDA package describes JLK-ICH as an image analysis algorithm hosted on JLK servers, which receive head CT scans forwarded from CT scanners, and a mobile application for notification management. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "JLK-ICH comprises an image analysis algorithm hosted on JLK servers and a mobile application for notification management." … "The AI/ML-based algorithm is designed to analyze NCCT of the head scans forwarded from CT scanners to the JLK servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · JLK-ICH: K243363 decision and 510(k) summary

  4. Returned objects

    Source context, not route validation: Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes JLK-ICH as an image analysis algorithm hosted on JLK servers, which receive head CT scans forwarded from CT scanners, and a mobile application for notification management. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "JLK-ICH comprises an image analysis algorithm hosted on JLK servers and a mobile application for notification management." … "The AI/ML-based algorithm is designed to analyze NCCT of the head scans forwarded from CT scanners to the JLK servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
DICOM-compatible image transfer and processing; notifications are delivered through the JLK mobile application.
  • Exact FDA submission
  • Checked 2026-09-05
Security
JLK's security page states a security program aligned with SOC 2 and HIPAA, AWS hosting in US regions with VPC isolation, TLS 1.2+ in transit, AES-256 at rest with KMS, role-based access, mandatory MFA for internal users, annual external penetration testing and security training. It states alignment, not an attestation report. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Family stroke workflow

Vendor describes JLK-ICH as part of its MEDIHUB stroke portfolio.

product family · checked 2026-09-05

Current portfolio claims for other modalities and modules are not capabilities of K243363.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243363
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

The cleared input is NCCT; the catalog's CT/CTA controlled category does not imply CTA use.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
24Fields reviewed
12Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed candidate and publication metadata/full-text record reviewed; it names JLK-ICH but has company-employed authors and unestablished exact version, so retained only as non-independent product-family context. Stored trial array is empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No primary-source US commercial price reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "JLK ICH SDH reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Mobile-app notification response training and local escalation protocol remain unestablished.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Local notification latency, false-alert and missed-alert monitoring commitments require confirmation.

10 sources - 3 history items

Source ledger

  1. JLK-ICH: K243363 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Jlk-ich model card (K243363)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. JLK-ICH: K243363 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  8. MEDIHUB STROKE

    JLK - Accessed 2026-09-05

    Scope: implementation

  9. Deep learning-assisted detection of intracranial hemorrhage: validation and impact on reader performance

    Neuroradiology / PubMed - Published 2025-06-01 - Accessed 2026-09-06

    Scope: evidenceStudies

  10. JLK Security and Compliance

    JLK - Accessed 2026-10-25

    Scope: security

Research history

  1. K243363 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16
FDA-cleared K240353

Hyper Insight - ICH

SK Inc.

Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2024-07-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history